Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers | Zendy

Vincent Chung | Zendy; Ferdynand Kos | Zendy; Nicola Hardwick | Zendy; Yuan Yuan | Zendy; Joseph Chao | Zendy; D. Li | Zendy; James Waisman | Zendy; Minzhao Li | Zendy; Kathryn Zurcher | Zendy; Paul Frankel | Zendy; Don J. Diamond | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers

Author(s) -

Vincent Chung,

Ferdynand Kos,

Nicola Hardwick,

Yuan Yuan,

Joseph Chao,

D. Li,

James Waisman,

Minzhao Li,

Kathryn Zurcher,

Paul Frankel,

Don J. Diamond

Publication year - 2018

Publication title -

clinical and translational oncology

Language(s) - English

Resource type - Journals

eISSN - 1699-3055

pISSN - 1699-048X

DOI - 10.1007/s12094-018-1932-2

Subject(s) - medicine , pembrolizumab , immune system , modified vaccinia ankara , clinical trial , oncology , cancer , immunotherapy , breast cancer , immunology , vaccinia , biochemistry , chemistry , gene , recombinant dna

Vaccination of cancer patients with p53-expressing modified vaccinia Ankara virus (p53MVA) has shown in our previous studies to activate p53-reactive T cells in peripheral blood but without immediate clinical benefit. We hypothesized that the immunological responses to p53MVA vaccine may require additional immune checkpoint blockade to achieve clinically beneficial levels. We therefore conducted a phase I trial evaluating the combination of p53MVA and pembrolizumab (anti-PD-1) in patients with advanced solid tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research